Warburg Pincus could seek more representation on ZymoGenetics' board

By Lisa Kerner

Charlotte, N.C., March 12 - Warburg Pincus LLC said it may seek to have additional representation on the board of directors of ZymoGenetics Inc. after purchasing 1,587,039 shares of the company's stock.

Two of ZymoGenetics' nine board members are Warburg Pincus designees: Jonathan S. Leff, general partner of Warburg Pincus, and Dr. David I. Hirsh, executive vice president for research at Columbia University and a member of Warburg Pincus' life sciences advisory board.

The investor, with a 13.7% stake in the company, may also choose to discuss ZymoGenetics' business strategy and operations with its management, according to a schedule 13D filing with the Securities and Exchange Commission.

Warburg Pincus acquired the 1.58 million shares between Feb. 21 and March 10 priced from $8.46 to $10.10.

ZymoGenetics is a Seattle-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.